Day: November 11, 2025

The largest longitudinal study of psilocybin microdosing just revealed something unexpected. Mental health improved across everyone—younger and older alike. Depression dropped. Anxiety decreased. Mood lifted. That was expected. But motor function? That only improved in one group. Adults 55 and older. And only when they combined three specific compounds: psilocybin, Lion’s Mane mycelium, and niacin. Co-authored by mycologist Paul Stamets, this 2022 research published in Scientific Reports is the first to show age-dependent benefits from combining mushroom compounds. The study tracked 953 microdosers and 180 non-microdosers for 30 days, revealing a pattern that challenges how we think about interventions for aging brains. This article explores what they found, why it might work, and what it means for the future of healthy aging research. Who is Paul Stamets? Paul Stamets isn’t just a supplement entrepreneur. He’s a mycologist with over four decades of research, a published scientist, and one of the world’s leading advocates for the medicinal potential of mushrooms. You might know him from Netflix’s Fantastic Fungi or his appearances on the Joe Rogan podcast. But Stamets’ credentials run deeper than his public profile. He founded Fungi Perfecti in 1980 and has spent his career studying mycelium—the root-like network of mushrooms that he believes holds greater medicinal potential than the fruiting bodies most supplements use. His “Stamets Stack” became the most popular microdosing protocol in the world, not through marketing, but through grassroots adoption in microdosing communities. The combination is specific: psilocybin, Lion’s Mane mycelium, and niacin (vitamin B3). The rationale behind his stack: Psilocybin promotes neuroplasticity through 5-HT2A serotonin receptor activation. It helps the brain form new connections. Lion’s Mane mycelium stimulates nerve growth factor (NGF), supporting the physical growth and maintenance of neurons. Niacin causes vasodilation—the “flushing” effect that widens blood vessels. Stamets theorized this would enhance bioavailability, driving the other compounds across the blood-brain barrier more effectively. Three compounds. Three mechanisms. Potential synergy. But this wasn’t just theory. Stamets co-authored both the 2021 baseline study (8,703 participants from 84 countries) and the 2022 longitudinal follow-up we’re discussing today. He wasn’t lending his name—he was actively involved in the research design. Historical context matters here. The Aztecs combined psilocybin mushrooms with cacao in a preparation called “cacahua-xochitl.” Ancient wisdom recognized that combining compounds could produce different effects than single ingredients. Stamets modernized this approach with scientific specificity. The question his research asked: Does the combination actually work better than psilocybin alone? And if so, for whom? The Lion’s Mane Foundation: A Pattern Emerges If you read my earlier emails about Lion’s Mane, you already know this mushroom has a track record with aging brains. The Mori Study (2009): Japanese researchers gave Lion’s Mane to 50-80 year olds with mild cognitive impairment for 16 weeks. Cognitive function improved significantly compared to placebo. The benefits disappeared when they stopped taking it. This wasn’t a fringe study. It was published in Phytotherapy Research and remains one of the strongest human trials on Lion’s Mane. The Mechanism Study (2023): More recently, researchers at the University of Queensland identified how Lion’s Mane works. A compound called hericene A promotes neurotrophic activity—essentially telling brain cells to grow new connections. The study, published in the Journal of Neurochemistry, showed Lion’s Mane enhances neurite outgrowth in hippocampal neurons. This matters because it explains WHY the Mori study worked. It’s not placebo. It’s measurable biological activity. The pattern: Lion’s Mane alone shows cognitive benefits in older adults (50-80 age range). The mechanism involves nerve growth and brain connections. Now we’re seeing it as part of Stamets’ three-compound combination, and once again, the benefits appear specifically in older adults. A critical distinction: Stamets emphasizes mycelium over fruiting body. Animal studies suggest they contain different compounds and may produce different effects. Some research indicates mycelium promotes brain function while fruiting body extract may inhibit it. This becomes a limitation later—the study didn’t track which form participants used. With Lion’s Mane’s solo potential established, Stamets asked the next logical question: What happens when you combine it with psilocybin and niacin? Could synergistic effects produce outcomes beyond any single compound? The 2022 study set out to answer that question. The Study Design: How They Tested It Published: Scientific Reports (part of the Nature portfolio), 2022 Full title: “Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls” Sample: 953 microdosers, 180 non-microdosers Duration: Approximately 30 days of tracking Method: Mobile app-based observational study This was not a controlled clinical trial. It was an observational study, which means researchers didn’t give anyone psilocybin. They watched people who were already microdosing and compared them to people who weren’t. Why this methodology? Advantages: Real-world conditions. Large, diverse sample. Geographic spread (though predominantly North American). Anonymous participation via app reduced reporting bias. Limitations: No randomization. Self-selected participants (microdosers chose to microdose). Can’t prove causation, only association. Placebo effects can’t be ruled out. What they measured: Mental health: Depression (PHQ-9 scale), Anxiety (GAD-7 scale), Stress (Perceived Stress Scale) Psychomotor performance: Finger tap test Mood: Daily tracking via app Demographics: Age, gender, mental health status at baseline The finger tap test deserves explanation. It sounds simple, but it’s a validated neurological measure. Participants tap two circles on their phone screen in an alternating pattern for 10 seconds. The test measures motor speed, coordination, and response time—all markers of how well the brain and body communicate. This test appears in Parkinson’s research and aging studies because motor function often declines before cognitive function. Your hands slow down 5-10 years before memory problems appear. It’s an early warning system. The novel aspect: Stacking analysis Previous microdosing research treated all microdosers as one group. This study broke them into three subgroups: Psilocybin only (n=385, 40.4%) Psilocybin + Lion’s Mane (n=304, 31.9%) Psilocybin + Lion’s Mane + Niacin (n=264, 27.7%) — The full Stamets Stack This was the first research to examine whether combining compounds produces different outcomes than single compounds. The researchers also stratified by age: under 55 versus 55 and